The vulnerable atherosclerotic plaque: pathogenesis and therapeutic approach.
Aikawa
Masanori
M
Donald W. Reynolds Cardiovascular Clinical Research Centers, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. maikawa@rics.bwh.harvard.edu
Libby
Peter
P
D000818:Animals; D001808:Blood Vessels / Q000473:pathology*; D008078:Cholesterol, LDL / Q000187:drug effects / Q000378:metabolism; D003324:Coronary Artery Disease / Q000209:etiology* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy; D007249:Inflammation / Q000209:etiology / Q000473:pathology; D008077:Lipoproteins, LDL / Q000187:drug effects / Q000378:metabolism; D009203:Myocardial Infarction / Q000209:etiology / Q000473:pathology / Q000503:physiopathology
D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008077:Lipoproteins, LDL; C099252:oxidized low density lipoprotein